Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
LXRX
Stock Latest News
Ratings
Lexicon Pharmaceuticals: Promising Phase 2b Results and Strategic Plans Justify Buy Rating
5d ago
LXRX
Premium
The Fly
Lexicon presents additional pilavapadin data in DPNP
5d ago
LXRX
Premium
The Fly
Lexicon convenes roundtable on public policy gaps for chronic pain
11d ago
LXRX
Premium
The Fly
FDA informs Lexicon it requires additional time to review Zynquista NDA
26d ago
LXRX
Premium
Ratings
Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating
1M ago
LXRX
Premium
The Fly
Lexicon announces presents data from Phase 2 PROGRESS study for pilavapadin
1M ago
LXRX
Premium
Ratings
Promising Preclinical Data and FDA Alignment Support Buy Rating for Lexicon Pharmaceuticals’ Pilavapadin
1M ago
LXRX
Premium
Ratings
Lexicon Pharmaceuticals: Promising Drug Developments and Positive Regulatory Path Boost Buy Rating
1M ago
LXRX
Premium
The Fly
Lexicon submits additional data to FDA for benefit-risk profile of Zynquista
1M ago
LXRX
Premium
Ratings
Lexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy Rating
2M ago
LXRX
Premium
The Fly
Lexicon announces post-hoc analysis of clinical data presented at ESC
2M ago
LXRX
Premium
Company Announcements
Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy
2M ago
LXRX
Premium
Ratings
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges
2M ago
LXRX
Premium
The Fly
Citi ups Lexicon target, opens ‘upside catalyst watch’
2M ago
LXRX
Premium
Company Announcements
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results
2M ago
LXRX
Premium
Company Announcements
Lexicon Pharmaceuticals Reports Strong Q2 2025 Earnings
2M ago
LXRX
Premium
Ratings
Lexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating
2M ago
LXRX
Premium
The Fly
Lexicon reports Q2 EPS 1c, consensus (8c)
2M ago
LXRX
Premium
Pre-Earnings
LXRX Upcoming Earnings Report: What to Expect?
3M ago
LXRX
Premium
The Fly
Lexicon regains compliance with Nasdaq minimum bid price requirement
3M ago
LXRX
Premium
Company Announcements
Lexicon Pharmaceuticals Regains Nasdaq Compliance
3M ago
8K
LXRX
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
BMBL
BZAI
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
